Breaking News Instant updates and real-time market news.

GILD

Gilead

$79.12

1.26 (1.62%)

, MRK

Merck

$62.41

0.5 (0.81%)

07:47
10/03/16
10/03
07:47
10/03/16
07:47

AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink

Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.

GILD

Gilead

$79.12

1.26 (1.62%)

MRK

Merck

$62.41

0.5 (0.81%)

ABBV

AbbVie

$63.07

0.25 (0.40%)

  • 04

    Oct

  • 07

    Oct

  • 25

    Oct

  • 06

    Nov

  • 11

    Nov

GILD Gilead
$79.12

1.26 (1.62%)

09/27/16
LEER
09/27/16
DOWNGRADE
Target $94
LEER
Market Perform
Gilead downgraded to Market Perform from Outperform at Leerink
Leerink analyst Geoffrey Porges downgraded Gilead Sciences to Market Perform from Outperform and lowered his price target for the shares to $94 from $112. The biotech closed yesterday down 75c to $80.62. The analyst says he's now "outright bearish" on the company's Hepatitis C virus business. Gilead's HCV revenues will "decline faster, and farther," than the current consensus estimates forecast, Porges tells investors in a research note.
09/22/16
JANY
09/22/16
NO CHANGE
Target $64
JANY
Buy
Galapagos drug more important to Gilead after trial halt, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Gilead Sciences' (GILD) termination of its combined Phase 2/3 study of GS-5745 in ulcerative colitis implies that Galapagos (GLPG) filgotinib is now potentially more important to Gilead's growth prospects. The analyst, who thinks upcoming data could provide meaningful upside for Galapagos shares even after the stock's 25% move up over the past three weeks, keeps a Buy rating and $64 fair value estimate on the stock.
09/22/16
LEER
09/22/16
NO CHANGE
LEER
Outperform
Gilead trial suspension another blow to R&D strategy, says Leerink
Leerink analyst Geoffrey Porges believes Gilead's suspension of Phase 2/3 for GS-5745, its anti-matrix metalloproteinase 9 anti-body for the treatment of ulcerative colitis, is unlikely to significantly impact revenue forecasts for the company. However, he sees the announcement as another blow to the sentiment about the company's R&D prospects and investor sentiment. Further, Porges notes that GS-5745 was one of the five proof-of-concept molecules in Phase 2 development that offered opportunity for some offset to Gilead's "increasingly challenged" core businesses. He reiterates an Outperform rating on the shares.
09/27/16
09/27/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Gilead (GILD) downgraded to Market Perform from Outperform at Leerink with analyst Geoffrey Porges saying he's now "outright bearish" on the company's Hepatitis C virus business. 2. J.M. Smucker (SJM) downgraded to Neutral from Outperform at Credit Suisse with analyst Robert Moskow saying that while the company raised its cost savings target as expected, he underestimated the hit to sales from difficult comparisons. 3. Discovery (DISCA) and Scripps Networks (SNI) downgraded to Sell from Neutral at MoffettNathanson. 4. Carter's (CRI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Ike Boruchow saying his quarter-to-date store checks indicate "choppy" retail traffic trends and "deeper" pricing/promotional pressure. 5. Dollar Tree (DLTR) downgraded to Underweight from Neutral at Atlantic Equities with analyst Sam Hudson saying the second half comp inflection expected by consensus is "too demanding" and he expects multiple contraction if Family Dollar does not turn around. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MRK Merck
$62.41

0.5 (0.81%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
08/15/16
BERN
08/15/16
NO CHANGE
BERN
Survey of MDs suggest Merck's Keytruda being underestimated, says Bernstein
After Bernstein surveyed a total of 79 U.S. and EU doctors, analyst Tim Anderson says the impact of recent trials of Merck's (MRK) Keytruda and Bristol-Myers' (BMY) Opdivo will be "greater than many (investors) expect." Anderson says that the survey indicates that the positive implications on Merck and the negative impact on Bristol-Myers will not just be "a near-term phenomenon." The analyst continues to expect the impact of the recent data to be greater than the consensus outlook. He keeps a $74 price target and Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
08/19/16
UBSW
08/19/16
NO CHANGE
Target $70
UBSW
Buy
Merck price target raised to $70 from $62 at UBS
UBS analyst Marc Goodman raised his price target on Merck (MRK) to $70 from $62 as he updated his model to account for a more favorable Keytruda opportunity following the failed CheckMate-026 trial at Bristol-Myers (BMY). The analyst also feels investors do not give enough credit to Merck's Januvia franchise or the potential for growth opportunity from the pipeline. Goodman reiterated his Buy rating on Merck shares.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
ABBV AbbVie
$63.07

0.25 (0.40%)

09/08/16
JPMS
09/08/16
DOWNGRADE
Target $73
JPMS
Neutral
AbbVie downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Chris Schott downgraded AbbVie (ABBV) to Neutral citing the stock's 10% rally year-to-date and limited near-term catalysts. AbbVie's profile is now better reflected at current valuation levels, Schott tells investors in a research note. He lowered his price target for the shares to $73 from $75. The analyst coupled the downgrade with an upgrade this morning of Eli Lilly (LLY) to Overweight.
09/02/16
09/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AbbVie (ABBV) initiated with an Outperform at Raymond James. 2. Spark Therapeutics (ONCE) initiated with a Buy at Stifel. 3. Cornerstone OnDemand (CSOD) initiated with an Overweight at Piper Jaffray. 4. UR-Energy (URG) initiated with an Outperform at FBR Capital. 5. Energy Transfer Equity (ETE) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/01/16
RAJA
09/01/16
INITIATION
Target $82
RAJA
Outperform
AbbVie initiated with an Outperform at Raymond James
Target $82.
07/14/16
JEFF
07/14/16
NO CHANGE
JEFF
AbbVie remains Jefferies' Top Pick in Global Pharma
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his firm's Top Pick in Global Pharmaceuticals, followed by Eli Lilly (LLY), Novartis (NVS), GlaxoSmithKline (GSK) and Zoetis (ZTS). The analyst this morning upgraded GSK to Buy from Hold. Holford also remains positive on Roche (RHHBY), Abbott (ABT) and Pfizer (PFE). The analyst's least preferred names are Novo Nordisk (NVO), Johnson & Johnson (JNJ) and Merck (MRK). The Q2 earnings season offers "few clear beat and raise" stories and looks weakest for AstraZeneca (AZN) against preliminary consensus, Holford tells investors in a pre-earnings research note.

TODAY'S FREE FLY STORIES

RNVA

Rennova Health

$0.22

0.0086 (4.07%)

, CI

Cigna

09:35
09/25/17
09/25
09:35
09/25/17
09:35
Hot Stocks
Rennova Health announces appeals court win for Cigna suit »

Rennova Health (RNVA)…

RNVA

Rennova Health

$0.22

0.0086 (4.07%)

CI

Cigna

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDAIF

Daimler AG

$79.70

0.09 (0.11%)

09:31
09/25/17
09/25
09:31
09/25/17
09:31
Hot Stocks
Daimler Trucks tests truck platooning on public highways in the U.S. »

As the first commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPZ

Williams Partners

09:30
09/25/17
09/25
09:30
09/25/17
09:30
Initiation
Williams Partners initiated  »

Williams Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMB

Williams

09:30
09/25/17
09/25
09:30
09/25/17
09:30
Initiation
Williams initiated  »

Williams initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YUM

Yum! Brands

09:30
09/25/17
09/25
09:30
09/25/17
09:30
Recommendations
Yum! Brands analyst commentary  »

Yum! Brands' Taco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

ICPT

Intercept

$61.59

-12.11 (-16.43%)

09:30
09/25/17
09/25
09:30
09/25/17
09:30
Hot Stocks
Intercept says talks with FDA 'evolving' »

When asked on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SMMF

Summit Financial Group

$25.01

0.22 (0.89%)

09:30
09/25/17
09/25
09:30
09/25/17
09:30
Downgrade
Summit Financial Group rating change  »

Summit Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCMI

PCM, Inc.

$13.20

0.2 (1.54%)

09:29
09/25/17
09/25
09:29
09/25/17
09:29
Hot Stocks
PCM, Inc. acquires Stack Technology, subsidiaries »

PCM, Inc. has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

BIIB

Biogen

$318.46

3.43 (1.09%)

, NVO

Novo Nordisk

09:28
09/25/17
09/25
09:28
09/25/17
09:28
Hot Stocks
Biogen apponts Camille Lee as SVP, Alzheimer's Disease Therapeutic Area »

Biogen (BIIB) announced…

BIIB

Biogen

$318.46

3.43 (1.09%)

NVO

Novo Nordisk

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:27
09/25/17
09/25
09:27
09/25/17
09:27
Conference/Events
Wells Fargo financial team holds an analyst/industry conference call »

Wells Fargo Financial…

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

, PTN

Palatin

09:24
09/25/17
09/25
09:24
09/25/17
09:24
Hot Stocks
On The Fly: Pre-market Movers »

HIGHER: Exelixis (EXEL),…

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

PTN

Palatin

AGN

Allergan

ICPT

Intercept

$61.59

-12.11 (-16.43%)

GPC

Genuine Parts

TGT

Target

LLY

Eli Lilly

AAPL

Apple

$151.89

-1.5 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 30

    Oct

TSLA

Tesla

$351.09

-15.39 (-4.20%)

, GM

General Motors

09:24
09/25/17
09/25
09:24
09/25/17
09:24
Periodicals
China may ease foreign automaker rules aiding Tesla, WSJ reports »

China officials may ease…

TSLA

Tesla

$351.09

-15.39 (-4.20%)

GM

General Motors

VLKAY

Volkswagen

$34.57

0.46 (1.35%)

F

Ford

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Oct

  • 03

    Oct

  • 26

    Oct

SBRA

Sabra Health Care

$22.21

0.03 (0.14%)

09:23
09/25/17
09/25
09:23
09/25/17
09:23
Initiation
Sabra Health Care initiated  »

Sabra Health Care…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

09:20
09/25/17
09/25
09:20
09/25/17
09:20
General news
Treasury Action: supply is on tap this week »

Treasury Action: supply…

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
09/25/17
09/25
09:18
09/25/17
09:18
Options
Overnight activity included 98 trades in SPX and 33 trades in VIX »

98 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTNX

Nutanix

$24.50

1.04 (4.43%)

09:17
09/25/17
09/25
09:17
09/25/17
09:17
Recommendations
Nutanix analyst commentary  »

Nutanix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

09:16
09/25/17
09/25
09:16
09/25/17
09:16
Hot Stocks
Amazon signs first-look production deal with Casey Affleck's Sea Change Media »

Amazon Studios has closed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

09:15
09/25/17
09/25
09:15
09/25/17
09:15
General news
The Hurricane Lift for U.S. Producer Sentiment Has Begun: »

The Hurricane Lift for…

TUWOY

Tullow Oil

$1.19

0.08 (7.21%)

09:14
09/25/17
09/25
09:14
09/25/17
09:14
Upgrade
Tullow Oil rating change  »

Tullow Oil upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$151.89

-1.5 (-0.98%)

, S

Sprint

09:14
09/25/17
09/25
09:14
09/25/17
09:14
Recommendations
Apple, Sprint, STMicroelectronics analyst commentary  »

Initial Apple iPhone 8…

AAPL

Apple

$151.89

-1.5 (-0.98%)

S

Sprint

STM

STMicroelectronics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 22

    Oct

  • 16

    May

FINL

Finish Line

$9.73

0.51 (5.53%)

09:14
09/25/17
09/25
09:14
09/25/17
09:14
Recommendations
Finish Line analyst commentary  »

Finish Line takeout…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$64.33

-0.12 (-0.19%)

09:13
09/25/17
09/25
09:13
09/25/17
09:13
Recommendations
Carnival analyst commentary  »

Carnival estimates raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

YUM

Yum! Brands

09:13
09/25/17
09/25
09:13
09/25/17
09:13
Conference/Events
Yum! Brands management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

09:12
09/25/17
09/25
09:12
09/25/17
09:12
Hot Stocks
Amazon signs multi-year deal with Amy Sherman-Palladino, Daniel Palladino »

Amazon announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

MSM

MSC Industrial

09:11
09/25/17
09/25
09:11
09/25/17
09:11
Initiation
MSC Industrial initiated  »

MSC Industrial initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.